KR100302346B1 - A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline - Google Patents
A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline Download PDFInfo
- Publication number
- KR100302346B1 KR100302346B1 KR1019990004469A KR19990004469A KR100302346B1 KR 100302346 B1 KR100302346 B1 KR 100302346B1 KR 1019990004469 A KR1019990004469 A KR 1019990004469A KR 19990004469 A KR19990004469 A KR 19990004469A KR 100302346 B1 KR100302346 B1 KR 100302346B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- hydroxy
- oxo
- tetrahydroquinoline
- preparing
- Prior art date
Links
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 16
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- -1 4-substituted-aniline Chemical class 0.000 claims description 3
- 239000002841 Lewis acid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000007517 lewis acids Chemical class 0.000 claims description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 abstract description 7
- 229960004588 cilostazol Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001442129 Myosotis Species 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- YVLNDCLPPGIRCP-UHFFFAOYSA-N 2-nitro-3-phenylprop-2-enoic acid Chemical class OC(=O)C([N+]([O-])=O)=CC1=CC=CC=C1 YVLNDCLPPGIRCP-UHFFFAOYSA-N 0.000 description 1
- QVWAEZJXDYOKEH-UHFFFAOYSA-N 3-(3-hydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC(O)=C1 QVWAEZJXDYOKEH-UHFFFAOYSA-N 0.000 description 1
- UNDXPKDBFOOQFC-UHFFFAOYSA-N 4-[2-nitro-4-(trifluoromethyl)phenyl]morpholine Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1N1CCOCC1 UNDXPKDBFOOQFC-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 description 1
- XLYPHUGUKGMURE-UHFFFAOYSA-N 5-hydroxy-2-nitrobenzaldehyde Chemical compound OC1=CC=C([N+]([O-])=O)C(C=O)=C1 XLYPHUGUKGMURE-UHFFFAOYSA-N 0.000 description 1
- AQZGPSLYZOOYQP-UHFFFAOYSA-N Diisoamyl ether Chemical compound CC(C)CCOCCC(C)C AQZGPSLYZOOYQP-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/08—Halides
- B01J27/10—Chlorides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Abstract
본 발명은 혈전 치료제인 실로스타졸의 제조시 중간체로 유용한 화학식 1의 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린을 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline of formula (1) useful as an intermediate in the preparation of cilostazol, a thrombus therapeutic agent.
Description
본 발명은 실로스타졸(Cilostazol) 제조시에 중간체로 유용한 화학식 1의 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린을 제조하는 방법에 관한 것이다.The present invention relates to a process for preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline of formula (1) useful as an intermediate in the preparation of cilostazol.
실로스타졸은 혈전치료제로 사용되는 의약품으로서, 그 화학명은 6-[4-(1-시클로헥실-5-테트라졸릴)부톡시]-1,2,3,4-테트라히드로-2-옥소퀴놀린이고, 구조식은 하기 화학식 5와 같다.Cilostazol is a drug used as a thrombolytic agent, and its chemical name is 6- [4- (1-cyclohexyl-5-tetrazolyl) butoxy] -1,2,3,4-tetrahydro-2-oxoquinoline And, the structural formula is the same as the formula (5).
상기 화학식 5의 실로스타졸은 중간체로서 화학식 1의 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린과 5-할로부틸-1-시클로헥실테트라졸를 반응시켜 제조하고 있다[Chem. Pharm. Bull., Vol. 31, 1151~1157(1983)].The cilostazol of Formula 5 is prepared by reacting 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline and 5-halobutyl-1-cyclohexyl tetrazole of Formula 1 as an intermediate. Chem. Pharm. Bull., Vol. 31, 1151-1157 (1983).
화학식 1의 화합물 제조와 관련한 선행기술로서 화학식 1의 화합물과 유사한 화학식 7의 화합물을 제조하는 방법이 개시된 바 있다[Ber, Vol. 60, 858∼864(1927)]. 즉, 이 방법은 반응식 1에서 나타낸 바와 같이 화학식 6의 N-(4-치환-벤즈)-3-클로로프로피오닐아미드를 염화알루미늄으로 산 촉매화하여 용융상태에서 고리화반응에 의해 화학식 7의 화합물을 제조한다.As a prior art with regard to the preparation of compounds of formula (1), methods for preparing compounds of formula (7) similar to those of formula (1) have been disclosed. 60, 858-864 (1927). In other words, this process is characterized by the acid-catalyzed N- (4-substituted-benz) -3-chloropropionylamide of formula 6 with aluminum chloride, as shown in Scheme 1, to obtain a compound of formula 7 by cyclization in the molten state. To prepare.
상기 식에서 X는 수소원자, 클로로, 아미노, 페닐, 메틸 또는 에톡시기이다.Wherein X is a hydrogen atom, chloro, amino, phenyl, methyl or ethoxy group.
이 방법의 주요 단점은 용매를 사용하지 않고 유독성 고체인 염화알루미늄과화학식 6의 화합물을 혼합하여 초고온(200∼240℃)에서 반응시킴으로써 이에 따른 특수장치가 필요하여 산업화가 곤란하고, 불균일한 반응으로 골고루 반응시키기 어렵기 때문에 부반응에 따른 순도가 낮아 재결정 등의 추가 공정이 필요하고, 목적물의 수율도 낮아(80%) 경제성이 없으며 또한 위험성이 수반된다는 점이다.The main drawback of this method is that it is difficult to industrialize due to the nonuniform reaction by mixing a toxic solid aluminum chloride and a compound of Chemical Formula 6 without using a solvent and reacting it at an extremely high temperature (200-240 ° C.). Since it is difficult to react evenly, it is necessary to perform additional processes such as recrystallization due to low purity due to side reactions, and low yield (80%) of the target product, which is not economical and involves risk.
또한, 니트로신남산 유도체를 경유하여 화학식 1의 화합물을 제조하는 방법이 개시된 바 있다 [참조: Journal of the American Chemical Society, Vol. 66, 1442∼1443(1944)]. 이 방법은 반응식 2에 나타낸 바와 같이 화학식 10의 5-히드록시-2-니트로신남산 알킬로부터 환원반응 및 고리화반응에 의해 화학식 1의 화합물을 제조하는 방법이다.In addition, a method of preparing a compound of Formula 1 via a nitrocinnamic acid derivative has been disclosed. See Journal of the American Chemical Society, Vol. 66, 1442-1443 (1944). This method is a method for preparing the compound of formula 1 by reduction and cyclization from 5-hydroxy-2-nitrocinnamic acid alkyl of formula 10 as shown in Scheme 2.
상기 식에서 R은 수소원자, 메틸 또는 에틸기이다.R is a hydrogen atom, methyl or ethyl group.
이 방법은 화학식 10의 출발물질인 화학식 8의 5-히드록시-2-니트로벤즈알데히드 및 화학식 9의 3-히드록시신남산 알킬이 매우 고가이며 가압 조건에서 반응을 수행하므로 폭발의 위험성이 있고 가수소반응을 위해 압축된 기체를 취급하기 위한 특수장치가 필요하며 발화의 위험성이 매우 큰 수소를 사용하므로 공업화에 어려움이 있다는 단점이 있다.This method is very expensive and the reaction is carried out under pressurized conditions, since 5-hydroxy-2-nitrobenzaldehyde of formula 8 and alkyl hydroxy 3-nacinaldehyde of formula 9, which are starting materials of formula 10, have a risk of explosion and hydrogen It requires a special device for handling the compressed gas for the reaction and there is a disadvantage in that it is difficult to industrialize because it uses a very high risk of ignition.
신남산 유도체를 사용하여 화학식 1의 화합물을 제조하는 방법이 또한 개시된 바 있다[Journal of the American Chemical Society, Vol. 89, 7131∼7132(1962)]. 이 방법은 반응식 3에 나타낸 바와 같이 화학식 13의 3-히드록시신나모히드로사믹산으로부터 고리화반응에 의해 화학식 1의 화합물을 제조하는 방법이다.A process for preparing a compound of Formula 1 using cinnamic acid derivatives has also been disclosed. Journal of the American Chemical Society, Vol. 89, 7131-7132 (1962). This method is a method for preparing a compound of formula 1 by cyclization from 3-hydroxycinnamohydrosamic acid of formula 13 as shown in Scheme 3.
이 방법의 주요 단점은 화학식 13의 출발물질인 화학식 11의 3-(3-히드록시페닐)프로피온산이 매우 고가이고 출발물질로부터 3단계의 제조공정을 거쳐서 제조하는 방법으로 반응 경로가 길어서 비효율적이며 마지막 공정의 수율도 52%로서 저조하다는 점이다.The main drawback of this method is that the 3- (3-hydroxyphenyl) propionic acid of formula 11, which is the starting material of formula 13, is very expensive and is prepared in three steps from the starting material. The yield of the process is also low as 52%.
또한, 화학식 1의 화합물과 유사한 화학식 16의 화합물을 제조하는 방법이 개시된 바 있다[참조: Journal of Organic Chemistry, Vol. 36, 3975∼3979(1971)]. 이 방법은 화학식 14의 4-치환-아크릴아닐리드로부터 고리화반응에 의해 화학식 15의 화합물을 합성한 후 다시 탈알킬화반응에 의해 화학식 16의 6-히드록시-3-치환-4-히드로카보스티릴을 제조하는 방법이다.In addition, methods for preparing compounds of Formula 16 that are similar to those of Formula 1 have been disclosed. See Journal of Organic Chemistry, Vol. 36, 3975-3979 (1971). This method synthesized the compound of formula 15 by cyclization from 4-substituted-acrylanilide of formula 14 and then dealkylation reaction to 6-hydroxy-3-substituted-4-hydrocarbostyryl of formula 16. It is a method of manufacturing.
상기 식에서 R은 수소, 메틸 또는 에틸기이며, R1은 알킬 또는 전자주게 그룹(electron donating group)이다.Wherein R is hydrogen, methyl or ethyl, and R 1 is an alkyl or electron donating group.
이 방법의 주요 단점은 광 반응로서 공업적으로 부적절하며 화학식 15의 화합물로의 광 반응시 그 수율이 13%로서 매우 저조하다는 점이다.The main disadvantage of this method is that it is industrially inadequate as a photoreaction and its yield is very low as 13% upon photoreaction with a compound of formula 15.
따라서, 본 발명자들은 상기와 같은 종래 제조방법 상의 문제점을 해결하기 위하여 연구 노력한 결과, 안전하고 간단하게 수율이 높은 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린을 제조할 수 있는 본 발명을 완성하게 되었다.Accordingly, the present inventors have made efforts to solve the problems of the conventional manufacturing method as described above, the production of safe and simple high yield 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline. The present invention can be completed.
따라서 본 발명은 화학식 1의 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린의 제조방법을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a method for preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline of formula (1).
본 발명은 화학식 2의 N-(4-치환-벤즈)-3-클로로프로피오닐아미드를 균일화제의 존재하에서 루이스 산과 반응시키는 공정을 포함하는 화학식 1의 6-히드록시-2-옥소-1,2,3,4-테트라히드로 퀴놀린의 제조방법에 관한 것이다.The present invention provides a process for reacting N- (4-substituted-benz) -3-chloropropionylamide of formula (2) with Lewis acid in the presence of a homogenizing agent, 6-hydroxy-2-oxo-1 of formula (1), It relates to a method for producing 2,3,4-tetrahydroquinoline.
본 발명의 반응 경로를 반응식으로 나타내면 반응식 5와 같다.Reaction path of the present invention is represented by the reaction scheme 5.
상기 식에서 R은 수소, 메틸 또는 에틸이다.In which R is hydrogen, methyl or ethyl.
균일화제는 두 가지 이상의 반응물질을 균일하게 혼탁시켜 용융상태에서의 반응시 문제점인 불균일한 반응진행과 열전달의 감소를 완화시켜 줌으로써 미반응물 없이 보다 낮은 온도에서 균일하게 반응시키도록 도와주는 용제로서, 본 발명에 따른 제조방법에서 사용가능한 균일화제로는 데카히드로나프탈렌 (decahydronaphthalene); 디페닐 에테르(diphenyl ether), 이소아밀 에테르 (isoamyl ether), 벤질에틸 에테르(benzylethyl ether), 디글림(diglyme), 트리글림(triglyme) 등과 같은 고비점의 에테르 화합물; 또는 β-피넨(β-pinene), 리모넨(limonene), 테트랄린(tetraline) 등의 탄화수소 화합물이 있다. 이중 데카히드로나프탈렌이 가장 바람직하다.Homogenizer is a solvent that helps to uniformly react at lower temperature without unreacted material by quenching uniformly turbidity of two or more reactants to alleviate the uneven reaction progress and the decrease of heat transfer which are problems in the reaction in the molten state. Homogenizing agents usable in the production process according to the invention include decahydronaphthalene; High boiling ether compounds such as diphenyl ether, isoamyl ether, benzylethyl ether, diglyme, triglyme and the like; Or hydrocarbon compounds such as β-pinene, limonene, tetraline and the like. Most preferred is decahydronaphthalene.
본 발명에 따른 제조방법에서 사용가능한 루이스 산 촉매로는 염화알루미늄, 염화아연 또는 사염화티타늄이 있으며, 이중 염화알루미늄이 바람직하다.Lewis acid catalysts usable in the production process according to the invention include aluminum chloride, zinc chloride or titanium tetrachloride, of which aluminum chloride is preferred.
반응조건은 0∼200℃에서 2∼18시간동안 수행되는 것이 바람직하다.The reaction conditions are preferably carried out at 0 to 200 ° C. for 2 to 18 hours.
출발물질로 사용되는 화학식 2의 화합물은 화학식 3의 4-치환-아닐린을 화학식 4의 3-클로로프로피오닐 클로라이드와 반응시켜 고수율(97%)로 얻을 수 있다.The compound of formula 2 used as starting material can be obtained in high yield (97%) by reacting 4-substituted-aniline of formula 3 with 3-chloropropionyl chloride of formula 4.
이때 반응조건은 에틸 에세테이트, 디메틸포름아미드 및 디메틸술폭시드와 같은 극성 유기용매 또는 헥산 및 벤젠 등과 같은 비극성 유기 용매내에서 5℃ 내지 100℃의 온도에서 수행하는 것이 바람직하다.At this time, the reaction conditions are preferably carried out at a temperature of 5 ℃ to 100 ℃ in a polar organic solvent such as ethyl acetate, dimethylformamide and dimethyl sulfoxide or a non-polar organic solvent such as hexane and benzene.
본 발명의 공정에 따라 제조된 화학식 1의 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린은 혈전 치료제로 유용한 약제인 실로스타졸의 제조시 중간체로 사용될 수 있다.The 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline of formula 1 prepared according to the process of the present invention can be used as an intermediate in the preparation of cilostazol, a medicament useful as a therapeutic agent for thrombosis.
하기 실시예는 전술한 본 발명을 설명하기 위해 기술되나 이는 본 발명의 범위를 제한하는 것은 아니다.The following examples are set forth to illustrate the invention described above but are not intended to limit the scope of the invention.
실시예 1: N-(4-히드록시벤즈)-3-클로로프로피오닐아미드(2)의 제조Example 1: Preparation of N- (4-hydroxybenz) -3-chloropropionylamide (2)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 에틸 아세테이트1000ml, 4-히드록시아닐린 109.1g(1mol)을 가하고 실온에서 에틸 아세테이트 500ml에 희석된 3-클로로프로피오닐 클로라이드 190.5g(1.5mol)을 서서히 적가한 다음 1시간 동안 격렬하게 교반시켰다. 상기 반응액에 포화 탄산나트륨 1000ml를 가하여 염을 완전히 용해시킨 후 유기층을 분리하고 다시 유기층을 물 500ml로 세척한 후 분리된 유기층을 망초로 건조하고 감압증류하여 용매를 제거한 후 잔사를 이소프로판올과 물중에서 결정화하여 연보라색의 N-(4-히드록시벤즈)-3-클로로프로피오닐아미드 189.7g(95%)을 얻었다.1000 ml of ethyl acetate and 109.1 g (1 mol) of 4-hydroxyaniline were added to a flask equipped with a magnetic stirrer under nitrogen stream, and 190.5 g (1.5 mol) of 3-chloropropionyl chloride diluted in 500 ml of ethyl acetate was slowly added dropwise at room temperature. Stir vigorously for the next 1 hour. 1000 ml of saturated sodium carbonate was added to the reaction solution to completely dissolve the salt. The organic layer was separated, and the organic layer was washed with 500 ml of water again. The separated organic layer was dried with forget-me-not and distilled under reduced pressure to remove the solvent, and the residue was crystallized in isopropanol and water. This gave 189.7 g (95%) of light purple N- (4-hydroxybenz) -3-chloropropionylamide.
융점: 127˚ 내지 129˚(실측: 128˚ 내지 129˚)Melting Point: 127 ° to 129 ° (Measured: 128 ° to 129 °)
IR:νmax(cm-1) 3300 (N-H strech), 3200 (O-H strech), 1655 (C=O strech),IR: ν max (cm −1 ) 3300 (NH strech), 3200 (OH strech), 1655 (C = O strech),
1561, 1508, 1412, 1264, 1200, 980, 8391561, 1508, 1412, 1264, 1200, 980, 839
H1NMR: δ 2.75 (2H, t, ClCH2CH 2CO-)H 1 NMR: δ 2.75 (2H, t, ClCH 2 C H 2 CO—)
3.86 (2H, t, ClCH 2CH2CO-)3.86 (2H, t, ClC H 2 CH 2 CO-)
6.67∼7.38 (4H, q, Aromatic CH-)6.67 ~ 7.38 (4H, q, Aromatic C H- )
9.17 (1H, s,HOPh-)9.17 (1H, s, H OPh-)
9.79 (1H, s, ClCH2CH2CONH-)9.79 (1H, s, ClCH 2 CH 2 CON H- )
실시예 2: N-(4-메톡시벤즈)-3-클로로프로피오닐아미드(2)의 제조Example 2: Preparation of N- (4-methoxybenz) -3-chloropropionylamide (2)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 에틸 아세테이트1000ml, 4-메톡시아닐린 123.2g(1mol)을 가하고 실온에서 에틸 아세테이트 500ml에 희석된 3-클로로프로피오닐 클로라이드 190.5g(1.5mol)을 서서히 적가한 다음 1시간 동안 격렬하게 교반시켰다. 상기 반응액에 포화 탄산나트륨 1000ml를 가하여 염을 완전히 용해시킨 후 유기층을 분리하고 다시 유기층을 물 500ml로 세척한 후 분리된 유기층을 망초로 건조하고 감압증류하여 용매를 제거한 후 잔사를 이소프로판올과 물중에서 결정화하여 연보라색의 N-(4-메톡시벤즈)-3-클로로프로피오닐아미드 207.3g(97%)을 얻었다.1000 ml of ethyl acetate and 123.2 g (1 mol) of 4-methoxyaniline were added to a flask equipped with a magnetic stirrer under nitrogen stream, and 190.5 g (1.5 mol) of 3-chloropropionyl chloride diluted in 500 ml of ethyl acetate was slowly added dropwise at room temperature. Stir vigorously for the next 1 hour. 1000 ml of saturated sodium carbonate was added to the reaction solution to completely dissolve the salt. The organic layer was separated, and the organic layer was washed with 500 ml of water again. The separated organic layer was dried with forget-me-not and distilled under reduced pressure to remove the solvent, and the residue was crystallized in isopropanol and water. To give 207.3 g (97%) of light purple N- (4-methoxybenz) -3-chloropropionylamide.
융점: 120˚ 내지 122˚(실측: 121˚ 내지 122˚)Melting Point: 120 ° to 122 ° (Actual: 121 ° to 122 °)
IR:νmax(cm-1) 3275 (N-H strech), 1653 (C=O strech), 1605, 1549, 1512, 1301, 1244, 1030, 929, 829IR: ν max (cm -1 ) 3275 (NH strech), 1653 (C = O strech), 1605, 1549, 1512, 1301, 1244, 1030, 929, 829
H1NMR: δ 2.79 (2H, t, ClCH2CH 2 CO-)H 1 NMR: δ 2.79 (2H, t, ClCH 2 C H 2 CO-)
3.79 (3H, s, CH 3 OPh-)3.79 (3H, s, C H 3 OPh-)
3.88 (2H, t, ClCH 2 CH2CO-)3.88 (2H, t, Cl CH 2 CH 2 CO-)
6.85∼7.43 (4H, q, Aromatic CH-)6.85-7.43 (4H, q, Aromatic C H- )
7.43 (1H, s, ClCH2CH2CONH-)7.43 (1H, s, ClCH 2 CH 2 CON H- )
실시예 3: N-(4-에톡시벤즈)-3-클로로프로피오닐아미드(2)의 제조Example 3: Preparation of N- (4-ethoxybenz) -3-chloropropionylamide (2)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 에틸 아세테이트1000ml, 4-에톡시아닐린 137.2g(1mol)을 가하고 실온에서 에틸 아세테이트 500ml에 희석된 3-클로로프로피오닐 클로라이드 190.5g(1.5mol)을 서서히 적가한 다음 1시간 동안 격렬하게 교반시켰다. 상기 반응액에 포화 탄산나트륨 1000ml를 가하여 염을 완전히 용해시킨 후 유기층을 분리하고 다시 유기층을 물 500ml로 세척한 후 분리된 유기층을 망초로 건조하고 감압증류하여 용매를 제거한 후 잔사를 이소프로판올과 물중에서 결정화하여 연보라색의 N-(4-에톡시벤즈)-3-클로로프로피오닐아미드 214.0g(94%)을 얻었다.1000 ml of ethyl acetate and 137.2 g (1 mol) of 4-ethoxyaniline were added to a flask equipped with a magnetic stirrer under nitrogen stream, and 190.5 g (1.5 mol) of 3-chloropropionyl chloride diluted in 500 ml of ethyl acetate was slowly added dropwise at room temperature. Stir vigorously for the next 1 hour. 1000 ml of saturated sodium carbonate was added to the reaction solution to completely dissolve the salt. The organic layer was separated, and the organic layer was washed with 500 ml of water again. The separated organic layer was dried with forget-me-not and distilled under reduced pressure to remove the solvent, and the residue was crystallized in isopropanol and water. To give 214.0 g (94%) of light purple N- (4-ethoxybenz) -3-chloropropionylamide.
융점: 117˚ 내지 119˚(실측: 118˚ 내지 119˚)Melting Point: 117 ° to 119 ° (Measured: 118 ° to 119 °)
IR:νmax(cm-1) 3280 (N-H strech), 1653 (C=O strech), 1605, 1548, 1511,IR: ν max (cm -1 ) 3280 (NH strech), 1653 (C = O strech), 1605, 1548, 1511,
1308, 1241, 1047, 931, 8301308, 1241, 1047, 931, 830
H1NMR: δ 1.40 (3H, t, CH 3 CH2OPh-)H 1 NMR: δ 1.40 (3H, t, C H 3 CH 2 OPh-)
2.77 (2H, t, ClCH2CH 2 CO-)2.77 (2H, t, ClCH 2 C H 2 CO-)
3.86 (2H, t, ClCH 2CH2CO-)3.86 (2H, t, ClC H 2 CH 2 CO-)
4.01 (2H, q, CH3CH 2OPh-)4.01 (2H, q, CH 3 C H 2 OPh-)
6.82∼7.40 (4H, q, Aromatic CH-)6.82-7.40 (4H, q, Aromatic C H- )
7.56 (1H, s, ClCH2CH2CONH-)7.56 (1H, s, ClCH 2 CH 2 CON H- )
실시예 4: 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린(1)의 제조Example 4: Preparation of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline (1)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 데카히드로나프탈렌 500ml, N-(4-히드록시벤즈)-3-클로로프로피오닐아미드 199.1g(1mol) 및 염화알루미늄 667g(5mol)을 넣은 다음 실온에서 서서히 온도를 상승시켜 150℃에서 8시간 동안 교반하여 반응시켰다. 이들 생성된 고체를 5℃로 냉각시키고 물(1000ml)과 클로로포름(1000ml)을 가하여 고체를 격렬히 교반하여 분쇄시킨 후 여과하고 물 및 클로로포름으로 세척하였다. 여과된 생성물을 진공건조시켜 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린 146.9g(90%)을 얻었다.500 ml of decahydronaphthalene, 199.1 g (1 mol) of N- (4-hydroxybenz) -3-chloropropionylamide, and 667 g (5 mol) of aluminum chloride were added to a flask equipped with a magnetic stirrer under a nitrogen stream, and then gradually cooled to room temperature. The reaction mixture was stirred for 8 hours at 150 ° C. The resulting solid was cooled to 5 ° C., water (1000 ml) and chloroform (1000 ml) were added, the solid was vigorously stirred and triturated, filtered and washed with water and chloroform. The filtered product was vacuum dried to yield 146.9 g (90%) of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline.
융점: 235˚ 내지 237˚(실측: 236˚ 내지 237˚)Melting Point: 235 ° to 237 ° (Actual: 236 ° to 237 °)
IR:νmax(cm-1) 3315 (N-H strech), 3200 (O-H strech), 1649 (C=O strech)IR: ν max (cm -1 ) 3315 (NH strech), 3200 (OH strech), 1649 (C = O strech)
1502, 1392, 1287, 1252, 1151, 1116, 963, 813, 7771502, 1392, 1287, 1252, 1151, 1116, 963, 813, 777
H1NMR: δ 2.35 (2H, t, -CH2CH 2 CO-)H 1 NMR: δ 2.35 (2H, t, -CH 2 C H 2 CO-)
2.76 (2H, t, -CH 2 CH2CO-)2.76 (2H, t, -C H 2 CH 2 CO-)
6.51∼6.66 (3H, m, Aromatic CH-)6.51 to 6.66 (3H, m, Aromatic C H- )
9.00 (1H, s,HOPh-)9.00 (1H, s, H OPh-)
9.79 (1H, s, -CH2CH2CONH-)9.79 (1H, s, -CH 2 CH 2 CON H- )
실시예 5: 6-히드록시벤즈-2-옥소-1,2,3,4-테트라히드로퀴놀린(1)의 제조Example 5: Preparation of 6-hydroxybenz-2-oxo-1,2,3,4-tetrahydroquinoline (1)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 데카히드로나프탈렌 500ml, N-(4-메톡시벤즈)-3-클로로프로피오닐아미드 213.7g(1mol) 및 염화알루미늄 667g(5mol)를 넣은 다음 실온에서 서서히 온도를 상승시켜 150℃에서 8시간 동안 교반하여 반응시켰다. 이들 생성된 고체를 5℃로 냉각시키고 물(1000ml)과 클로로포름(1000ml)을 가하여 고체를 격렬히 교반하여 분쇄시킨 후 여과하고 물 및 클로로포름으로 세척하였다. 여과된 생성물을 진공건조시켜 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린 155.0g(95%)을 수득하였다.500 ml of decahydronaphthalene, 213.7 g (1 mol) of N- (4-methoxybenz) -3-chloropropionylamide and 667 g (5 mol) of aluminum chloride were added to a flask equipped with a magnetic stirrer under a nitrogen stream, and then gradually cooled to room temperature. The reaction mixture was stirred for 8 hours at 150 ° C. The resulting solid was cooled to 5 ° C., water (1000 ml) and chloroform (1000 ml) were added, the solid was vigorously stirred and triturated, filtered and washed with water and chloroform. The filtered product was dried in vacuo to yield 155.0 g (95%) of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline.
융점, IR, H1NMR 데이터는 실시예 4와 동일하다.Melting point, IR, H 1 NMR data are the same as in Example 4.
실시예 6: 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린(1)의 제조Example 6: Preparation of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline (1)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 데카히드로나프탈렌 500ml, N-(4-에톡시벤즈)-3-클로로프로피오닐아미드 227.7g(1mol) 및 염화알루미늄 667g(5mol)를 넣은 다음 실온에서 서서히 온도를 상승시켜 150℃에서 8시간 동안 교반하여 반응시켰다. 이들 생성된 고체를 5℃로 냉각시키고 물(1000ml)과 클로로포름(1000ml)을 가하여 고체를 격렬히 교반하여 분쇄시킨 후 여과하고 물 및 클로로포름으로 세척하였다. 여과된 생성물을 진공건조시켜 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린 145.2g(89%)을 수득하였다.500 ml of decahydronaphthalene, 227.7 g (1 mol) of N- (4-ethoxybenz) -3-chloropropionylamide and 667 g (5 mol) of aluminum chloride were placed in a flask equipped with a magnetic stirrer under a nitrogen stream, and then gradually cooled to room temperature. The reaction mixture was stirred for 8 hours at 150 ° C. The resulting solid was cooled to 5 ° C., water (1000 ml) and chloroform (1000 ml) were added, the solid was vigorously stirred and triturated, filtered and washed with water and chloroform. The filtered product was dried in vacuo to yield 145.2 g (89%) of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline.
융점, IR, H1NMR 데이터는 실시예 4와 동일하다.Melting point, IR, H 1 NMR data are the same as in Example 4.
실시예 7: 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린(1)의 제조Example 7: Preparation of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline (1)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 데카히드로나프탈렌 500ml, N-(4-메톡시벤즈)-3-클로로프로피오닐아미드 213.7g(1mol) 및 염화아연 681.5g(5mol)를 넣은 다음 실온에서 서서히 온도를 상승시켜 150℃에서 12시간 동안 교반하여 반응시켰다. 이들 생성된 고체를 5℃로 냉각시키고 물(1000ml)과 클로로포름(1000ml)을 가하여 고체를 격렬히 교반하여 분쇄시킨 후 여과하고 물 및 클로로포름으로 세척하였다. 여과된 생성물을 진공건조시켜 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린 143.6g(88%)을 수득하였다.500 ml of decahydronaphthalene, 213.7 g (1 mol) of N- (4-methoxybenz) -3-chloropropionylamide and 681.5 g (5 mol) of zinc chloride were added to a flask equipped with a magnetic stirrer under a nitrogen stream, and then slowly at room temperature. The temperature was raised and reacted by stirring at 150 ° C. for 12 hours. The resulting solid was cooled to 5 ° C., water (1000 ml) and chloroform (1000 ml) were added, the solid was vigorously stirred and triturated, filtered and washed with water and chloroform. The filtered product was vacuum dried to yield 143.6 g (88%) of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline.
융점, IR, H1NMR 데이터는 실시예 4와 동일하다.Melting point, IR, H 1 NMR data are the same as in Example 4.
실시예 8: 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린(1)의 제조Example 8: Preparation of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline (1)
질소 기류하에 자기 교반기가 장착된 플라스크 내에 데카히드로나프탈렌 500ml, N-(4-메톡시벤즈)-3-클로로프로피오닐아미드 213.7g (1 mol) 및 사염화티타늄 948.5g (5 mol)를 넣은 다음 실온에서 서서히 온도를 상승시켜 150℃에서 16시간 동안 교반하여 반응시켰다. 이들 생성된 고체를 5℃로 냉각시키고 물 (1000ml)과 클로로포름 (1000ml)을 가하여 고체를 격렬히 교반하여 분쇄시킨 후 여과하고물 및 클로로포름으로 세척하였다. 여과된 생성물을 진공건조시켜 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린 133.8g(82%)을 수득하였다.In a flask equipped with a magnetic stirrer under a nitrogen stream, 500 ml of decahydronaphthalene, 213.7 g (1 mol) of N- (4-methoxybenz) -3-chloropropionylamide, and 948.5 g (5 mol) of titanium tetrachloride were added to a room temperature. The temperature was gradually raised at and reacted by stirring at 150 ° C. for 16 hours. The resulting solid was cooled to 5 ° C., water (1000 ml) and chloroform (1000 ml) were added, the solid was vigorously stirred and triturated, filtered and washed with water and chloroform. The filtered product was vacuum dried to give 133.8 g (82%) of 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline.
융점, IR, H1NMR 데이터는 실시예 4와 동일하다.Melting point, IR, H 1 NMR data are the same as in Example 4.
상술한 바와 같이 본 발명은 제조공정이 간단하면서도 부산물 형성이 거의 없고, 수율도 높은 6-히드록시-2-옥소-1,2,3,4-테트라히드로퀴놀린을 제조하는 우수한 방법을 제공한다. 이 화합물은 혈전치료제로 유용한 실로스타졸의 제조시 유용한 중간체로 사용될 수 있다.As described above, the present invention provides an excellent method for preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline, which has a simple manufacturing process, little by-product formation, and high yield. This compound can be used as a useful intermediate in the preparation of cilostazol, which is useful as a thrombolytic agent.
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990004469A KR100302346B1 (en) | 1999-02-09 | 1999-02-09 | A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline |
JP10801699A JP4173599B2 (en) | 1999-02-09 | 1999-04-15 | Process for producing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990004469A KR100302346B1 (en) | 1999-02-09 | 1999-02-09 | A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000055712A KR20000055712A (en) | 2000-09-15 |
KR100302346B1 true KR100302346B1 (en) | 2001-09-22 |
Family
ID=19573885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990004469A KR100302346B1 (en) | 1999-02-09 | 1999-02-09 | A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4173599B2 (en) |
KR (1) | KR100302346B1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825214B2 (en) | 2000-08-14 | 2004-11-30 | Teva Pharmaceutical Industries, Ltd. | Substantially pure cilostazol and processes for making same |
US20050101631A1 (en) | 2002-08-01 | 2005-05-12 | Otsuka Pharmaceuticals Company | Process for producing carbostyril derivatives |
ES2401914T3 (en) | 2007-04-25 | 2013-04-25 | Concert Pharmaceuticals Inc. | Cilostazol analogues |
CN105111190B (en) * | 2015-09-17 | 2017-11-07 | 浙江金立源药业有限公司 | A kind of synthetic method of Cilostazol |
CN107325078B (en) * | 2017-07-17 | 2020-01-07 | 烟台万润药业有限公司 | Preparation method of cilostazol |
-
1999
- 1999-02-09 KR KR1019990004469A patent/KR100302346B1/en active IP Right Grant
- 1999-04-15 JP JP10801699A patent/JP4173599B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
KR20000055712A (en) | 2000-09-15 |
JP4173599B2 (en) | 2008-10-29 |
JP2000229944A (en) | 2000-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116987112A (en) | Improved process for preparing aminopyrimidine derivatives | |
KR100302346B1 (en) | A method of preparing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline | |
ZA200301590B (en) | Process for the preparation of mesylates of piperazine derivatives. | |
EP1235795A1 (en) | Process for the preparation of sulfamides | |
KR20190013554A (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
EP0727424B1 (en) | Process for the preparation of sulfonylurea derivatives | |
EP0388620B1 (en) | Process for the preparation of o-carboxypyridyl- and o-carboxyquinolylimidazolinones | |
JP4032861B2 (en) | Process for producing β-oxonitrile derivative or alkali metal salt thereof | |
WO2003014067A1 (en) | PROCESS FOR PRODUCING ß-OXONITRILE COMPOUND OR ALKALI METAL SALT THEREOF | |
EP0591236B1 (en) | Process for the preparation of 5-(3-butyryl-2,4,6-trimethyl)-2-(1-(ethoxyimino)propyl)-3-hydroxycyclohex-2-en-1-one | |
EP0811612B1 (en) | Process for preparing dithiocarbonimide derivatives | |
JP2804559B2 (en) | Method for producing 2-chloro-5-chloromethylpyridine | |
JPH061776A (en) | Production of substituted pyrazinecarbonitrile | |
JPH05140157A (en) | Phenothiazine derivative | |
EP1179532B1 (en) | Process for the production of indole derivatives and intermediates therefor | |
AU2002241271B2 (en) | Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate | |
EP1471058B1 (en) | Process for producing 1,2,3-triazole compound | |
KR970001473B1 (en) | Method for preparing pyrazole sulfonyl chloride derivatives | |
JPH01143878A (en) | Production of silicon azide | |
EP0705266B1 (en) | Process for producing imidazole derivative | |
KR940010282B1 (en) | Method and derivative of cyano guanidine | |
JP3567248B2 (en) | Method for producing 1,2-benzisothiazolin-3-one compound | |
JPH0674250B2 (en) | Method for producing thiocarbamate derivative | |
KR0159511B1 (en) | New quinoline derivatives and their process | |
JPH07247263A (en) | Production of methylthiobenzene compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20101224 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20111228 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20150106 Year of fee payment: 17 |